Aurora Cannabis (TSE:ACB) Upgraded by BMO Capital Markets to “Hold” Rating

Aurora Cannabis (TSE:ACB) was upgraded by investment analysts at BMO Capital Markets to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. TD reduced their price target on shares of Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating on the stock in a research note on Friday, June 12th. Canaccord Genuity Group dropped their price objective on shares of Aurora Cannabis from C$6.50 to C$5.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of C$7.17.

Aurora Cannabis Stock Down 0.5%

ACB stock opened at C$4.15 on Wednesday. Aurora Cannabis has a 52 week low of C$3.59 and a 52 week high of C$9.33. The business has a 50-day simple moving average of C$4.08 and a 200 day simple moving average of C$4.63. The company has a quick ratio of 2.48, a current ratio of 5.36 and a debt-to-equity ratio of 4.30. The company has a market cap of C$257.06 million, a PE ratio of -1.94 and a beta of 0.25.

Aurora Cannabis (TSE:ACB) last released its earnings results on Wednesday, August 5th. The company reported C($0.07) EPS for the quarter. Aurora Cannabis had a negative net margin of 9.53% and a negative return on equity of 5.21%. The firm had revenue of C$67.55 million during the quarter. Sell-side analysts anticipate that Aurora Cannabis will post -0.22 EPS for the current fiscal year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.